{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:26:49Z","timestamp":1790116009285,"version":"4.0.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Cardiovascular Interventions"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.jcin.2021.02.022","type":"journal-article","created":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T19:14:53Z","timestamp":1617650093000},"page":"768-780","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI\u00a0Trial"],"prefix":"10.1016","volume":"14","author":[{"given":"Benjamin E.","family":"Peterson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ph.","family":"Gabriel Steg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Oldgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Maeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Zeymer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrun","family":"Halvorsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan H.","family":"Hohnloser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matias","family":"Nordaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Miede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Kleine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurri\u00ebn M.","family":"ten Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcin.2021.02.022_bib1","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","article-title":"Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 study","volume":"129","author":"Chugh","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2021.02.022_bib2","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ahj.2008.06.029","article-title":"Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis","volume":"156","author":"Goto","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.jcin.2021.02.022_bib3","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ijcard.2013.11.030","article-title":"Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH registry","volume":"170","author":"Ruff","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jcin.2021.02.022_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024964","article-title":"Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography","volume":"6","author":"Kralev","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jcin.2021.02.022_bib5","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomised controlled trial","volume":"367","author":"Connolly","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2021.02.022_bib6","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jcin.2021.02.022_bib7","first-page":"CD003333","article-title":"Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm","volume":"4","author":"Lip","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jcin.2021.02.022_bib8","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.amjcard.2009.06.027","article-title":"Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes","volume":"104","author":"Depta","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jcin.2021.02.022_bib9","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.jacc.2014.03.021","volume":"64","author":"January","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2021.02.022_bib10","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2021.02.022_bib11","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2021.02.022_bib12","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2021.02.022_bib13","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/14656566.2017.1329822","article-title":"Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention","volume":"18","author":"Pareek","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jcin.2021.02.022_bib14","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2021.02.022_bib15","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.jacc.2015.02.051","article-title":"When is a double better than a TRIPLE? Stenting in patients with atrial fibrillation","volume":"65","author":"Bhatt","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2021.02.022_bib16","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1161\/CIRCULATIONAHA.116.025923","article-title":"O\u00a0PIONEERs! The beginning of the end of full-dose triple therapy with warfarin?","volume":"135","author":"Bhatt","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2021.02.022_bib17","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/eurheartj\/ehy162","article-title":"Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials","volume":"39","author":"Golwala","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2021.02.022_bib18","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jacc.2015.06.027","article-title":"Apixaban plus mono versus dual antiplatelet therapy in acute coronary syndromes: insights from the APPRAISE-2 trial","volume":"66","author":"Hess","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2021.02.022_bib19","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.116.004395","article-title":"Antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a North American perspective\u20142016 update","volume":"9","author":"Angiolillo","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2021.02.022_bib20","article-title":"Safety and efficacy of double antithrombotic therapy with non\u2013vitamin k antagonist oral anticoagulants in patients with atrial fibrillation undergoing percutaneous coronary intervention: a systematic review and meta-analysis","volume":"9","author":"Capodanno","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jcin.2021.02.022_bib21","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jamacardio.2019.1880","article-title":"Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: a network meta-analysis of randomized controlled trials","volume":"4","author":"Lopes","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jcin.2021.02.022_bib22","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1161\/CIRCULATIONAHA.120.046534","article-title":"Risk\/benefit tradeoff of antithrombotic therapy in patients with atrial fibrillation early and late after an acute coronary syndrome or percutaneous coronary intervention: insights from AUGUSTUS","volume":"141","author":"Alexander","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2021.02.022_bib23","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/clc.22572","volume":"39","author":"Cannon","year":"2016","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jcin.2021.02.022_bib24","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2021.02.022_bib25","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2021.02.022_bib26","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.1983.1.11.710","article-title":"Analysis of survival by tumor response","volume":"1","author":"Anderson","year":"1983","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jcin.2021.02.022_bib27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/jama.297.2.joc60179","article-title":"Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation","volume":"297","author":"Eisenstein","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2021.02.022_bib28","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/CIRCOUTCOMES.110.957951","article-title":"Landmark analysis at the 25-year landmark point","volume":"4","author":"Dafni","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jcin.2021.02.022_bib29","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1161\/CIRCULATIONAHA.106.683995","article-title":"Late coronary stent thrombosis","volume":"116","author":"Windecker","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2021.02.022_bib30","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCOUTCOMES.108.807123","article-title":"Impact of age and medical comorbidity on the effectiveness of implantable cardioverter-defibrillators for primary prevention","volume":"2","author":"Chan","year":"2009","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jcin.2021.02.022_bib31","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1056\/NEJMoa1415447","article-title":"Trial of everolimus-eluting stents or bypass surgery for coronary disease","volume":"372","author":"Park","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2021.02.022_bib32","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jacc.2015.02.050","article-title":"Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial","volume":"65","author":"Fiedler","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2021.02.022_bib33","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/europace\/euy174","volume":"21","author":"Lip","year":"2019","journal-title":"Europace"},{"key":"10.1016\/j.jcin.2021.02.022_bib34","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/CIRCULATIONAHA.118.034722","article-title":"Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention","volume":"138","author":"Angiolillo","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2021.02.022_bib35","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jacc.2019.05.016","article-title":"Management of antithrombotic therapy in atrial fibrillation patients undergoing PCI: JACC state-of-the-art review","volume":"74","author":"Capodanno","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2021.02.022_bib36","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","article-title":"Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial","volume":"127","author":"Dans","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2021.02.022_bib37","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2021.02.022_bib38","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jacc.2020.09.011","volume":"77","author":"Kumbhani","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2021.02.022_bib39","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration\u00a0with the European Association of Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2021.02.022_bib40","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/CIRCULATIONAHA.120.050438","article-title":"Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American perspective: 2021 update","volume":"143","author":"Angiolillo","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2021.02.022_bib41","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2021.02.022_bib42","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2021.02.022_bib43","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2021.02.022_bib44","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1093\/eurheartj\/ehz059","article-title":"Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial","volume":"40","author":"Oldgren","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2021.02.022_bib45","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s11886-018-1045-0","article-title":"Management of anticoagulation in patients with atrial fibrillation undergoing PCI: double or triple therapy?","volume":"20","author":"Peterson","year":"2018","journal-title":"Curr Cardiol Rep"}],"container-title":["JACC: Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193687982100296X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193687982100296X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:13:38Z","timestamp":1761848018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S193687982100296X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S193687982100296X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcin.2021.02.022","relation":{},"ISSN":["1936-8798"],"issn-type":[{"value":"1936-8798","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI\u00a0Trial","name":"articletitle","label":"Article Title"},{"value":"JACC: Cardiovascular Interventions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcin.2021.02.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}